- Home
- FURY vs RPTX Comparison
FURY vs RPTX Comparison
Compare FURY & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | RPTX |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 92.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FURY | RPTX |
|---|---|---|
| Price | $0.59 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.40 | ★ $3.50 |
| AVG Volume (30 Days) | 554.5K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.89 |
| 52 Week High | $0.89 | $4.07 |
Technical Indicators
Market Signals| Indicator | FURY | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 60.84 |
| Support Level | $0.50 | $2.10 |
| Resistance Level | $0.63 | $2.22 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 71.38 | 73.08 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.